NCT04273516View on ClinicalTrials.gov

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 22, 2020

Primary Completion Date

April 10, 2023

Study Completion Date

April 30, 2023

Conditions
StrokePrevention
Interventions
DRUG

Rivaroxaban 2.5 Mg Oral Tablet

Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily

DRUG

Rivaroxaban placebo tablets

Placebo tablets add to ASA 80 mg daily that is standard treatment

Trial Locations (1)

Unknown

Bou- Ali Sina Hospital, Sari

All Listed Sponsors
lead

Mazandaran University of Medical Sciences

OTHER

NCT04273516 - Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS) | Biotech Hunter | Biotech Hunter